Company Profile

Adjuvance Technologies Inc
Profile last edited on: 8/18/2020      CAGE: 5NFJ7      UEI: C6L6GD4QGWG9

Business Identifier: Vaccine adjuvant design and manufacturing
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

116 West 22nd Street Suite 1
New York, NY 10010
Location: Single
Congr. District: 10
County: New York

Public Profile

Adjuvance Technologies is a privately held biopharmaceutical company organized around enabling important and fundamental breakthroughs in vaccine adjuvant design and manufacturing. Adjuvants are the critical components are added to many vaccines to improve the immune response. Adjuvance Technologies has developed the capability to synthesize saponin adjuvants such as QS-21, a critical component of the AS01 adjuvant developed by GSK. In addition, principals of the firm have synthesized a novel analogue, TQL1055, with improved attributes compared to QS-21.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Key People / Management

  Jay Tyler Martin -- CEO

  Sean Bennett -- CMO

  Jeffrey Gardner -- Co-Founder, Chief Business Officer

  Patrick Giljum -- CTO

  David Gin -- Co-Founder

  Philip O Livingston -- Co-Founder and Chief Scientific Officer

  Govindaswami Ragupathi

  Stephan Schulze -- CFO